Skip to main content
logo

Matthew Phipps

Stock Analyst at William Blair

(0.37)
# 4,301
Out of 5,132 analysts
3
Total ratings
n/a
Success rate
-6.7%
Average return
Main Sectors:
Healthcare
Top Industries:
BiotechnologyDrug Manufacturers - General

Stocks Rated by Matthew Phipps

NuCana
Aug 30, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $2.12
Upside: -
Amgen
May 3, 2024
Upgrades: Outperform
Price Target: n/a
Current: $369.19
Upside: -
NewAmsterdam Pharma Company
Dec 19, 2022
Initiates: Outperform
Price Target: n/a
Current: $34.63
Upside: -